Metformin


Biguanide / AMPK activator

A first-line type 2 diabetes biguanide derived from French lilac (Galega officinalis), increasingly investigated for longevity and cancer prevention applications.

Abstract

Metformin (Glucophage; 1,1-dimethylbiguanide; CAS 657-24-9; molecular formula C4H11N5; molecular weight 129.16) is a biguanide derived from guanidine, originally identified in the 1920s from the French lilac (Galega officinalis) and approved in Europe in 1957 and the United States in 1995 for type 2 diabetes. The compound is the most prescribed oral antihyperglycemic globally. Primary mechanism is mild inhibition of mitochondrial complex I producing AMPK activation, with downstream reduction in hepatic gluconeogenesis, improved insulin sensitivity in skeletal muscle, and reduced gut glucose absorption. Beyond diabetes management, metformin has accumulated evidence in cancer prevention (reduced incidence in diabetics), cardiovascular outcomes (UKPDS, in obese diabetics), and possible longevity effects. The TAME trial (Targeting Aging with Metformin) is investigating longevity endpoints in non-diabetic populations. Pharmacokinetics: plasma half-life 4 to 9 hours; oral bioavailability 50 to 60 percent; renally excreted unchanged. Lactic acidosis is the principal serious adverse event but is rare with appropriate renal function monitoring.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph